rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA.
rBCG30, a recombinant form of Bacillus Calmette-Guérin 30, is an investigational vaccine for tuberculosis created by the team under Marcus A. Horwitz at UCLA.